Tumor immunity after viral oncolysis.
作者信息
Cassel W A, Garrett R E
出版信息
J Bacteriol. 1966 Sep;92(3):792. doi: 10.1128/jb.92.3.792-.1966.
Abstract
摘要
相似文献
1
Tumor immunity after viral oncolysis.病毒溶瘤后的肿瘤免疫
J Bacteriol. 1966 Sep;92(3):792. doi: 10.1128/jb.92.3.792-.1966.
2
Contribution of antiviral immunity to oncolysis by Newcastle disease virus in a murine lymphoma.抗病毒免疫对新城疫病毒在小鼠淋巴瘤中溶瘤作用的贡献。
J Natl Cancer Inst. 1967 Dec;39(6):1089-97.
3
4
[Studies on viral immunotherapy of ascitic tumors in mice. I. Results of treatment with virus on Ehrlich and S180 ascitic tumor cells].[小鼠腹水瘤的病毒免疫疗法研究。I. 病毒对艾氏腹水瘤细胞和S180腹水瘤细胞的治疗结果]
Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 1984 Jun;6(3):213-6.
5
Interaction between subcutaneous and intraperitoneal transplants of the Ehrlich carcinoma; the possible role of anti-tumour antibody.
J Pathol. 1971 Oct;105(2):95-103. doi: 10.1002/path.1711050203.
6
Rejection of lethal tumors after subcutaneous inoculation: a phenomenon of antigenic expression?
J Natl Cancer Inst. 1967 Dec;39(6):1129-39.
7
Immunity against the Ehrlich ascites carcinoma produced by bacterial endotoxins.细菌内毒素产生的对艾氏腹水癌的免疫力。
Transplant Proc. 1969 Mar;1(1):124-5.
8
Effects of BCG (Romanian substrain) on the Ehrlich carcinoma in A2G mice.
Arch Roum Pathol Exp Microbiol. 1979 Jan-Mar;38(1):95-103.
9
Immunization of mice to Sarcoma 180 and Ehrlich carcinoma with ultraviolet-killed tumor vaccine.用紫外线灭活的肿瘤疫苗对小鼠进行肉瘤180和艾氏癌免疫接种。
Proc Soc Exp Biol Med. 1968 Jan;127(1):7-17. doi: 10.3181/00379727-127-32609.
10
Growth of subcutaneous grafts of some clones of Ehrlich ascites tumor in mice of different strains.
Arch Immunol Ther Exp (Warsz). 1966;14(6):711-6.
引用本文的文献
1
Newcastle Disease Virus at the Forefront of Cancer Immunotherapy.新城疫病毒在癌症免疫治疗前沿领域
Cancers (Basel). 2020 Nov 28;12(12):3552. doi: 10.3390/cancers12123552.
2
Design and Production of Newcastle Disease Virus for Intratumoral Immunomodulation.用于瘤内免疫调节的新城疫病毒的设计与生产。
Methods Mol Biol. 2020;2058:133-154. doi: 10.1007/978-1-4939-9794-7_9.
3
Breaking Therapy Resistance: An Update on Oncolytic Newcastle Disease Virus for Improvements of Cancer Therapy.突破治疗耐药性：溶瘤新城疫病毒改善癌症治疗的最新进展
Biomedicines. 2019 Aug 30;7(3):66. doi: 10.3390/biomedicines7030066.
4
From chemotherapy to biological therapy: A review of novel concepts to reduce the side effects of systemic cancer treatment (Review).从化疗到生物疗法：减少全身癌症治疗副作用的新概念综述（综述）。
Int J Oncol. 2019 Feb;54(2):407-419. doi: 10.3892/ijo.2018.4661. Epub 2018 Dec 10.
5
Fifty Years of Clinical Application of Newcastle Disease Virus: Time to Celebrate!新城疫病毒临床应用五十年：值得庆祝！
Biomedicines. 2016 Jul 20;4(3):16. doi: 10.3390/biomedicines4030016.
6
Immunobiology of Newcastle Disease Virus and Its Use for Prophylactic Vaccination in Poultry and as Adjuvant for Therapeutic Vaccination in Cancer Patients.新城疫病毒的免疫生物学及其在禽类预防性疫苗接种中的应用以及作为癌症患者治疗性疫苗接种佐剂的应用。
Int J Mol Sci. 2017 May 20;18(5):1103. doi: 10.3390/ijms18051103.
7
Oncogenes: The Passport for Viral Oncolysis Through PKR Inhibition.癌基因：通过抑制PKR实现病毒溶瘤的通行证。
Biomark Cancer. 2016 Jul 28;8:101-10. doi: 10.4137/BIC.S33378. eCollection 2016.
8
Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions.溶瘤性新城疫病毒在癌症治疗中的应用：旧挑战与新方向。
Future Microbiol. 2012 Mar;7(3):347-67. doi: 10.2217/fmb.12.4.
9
Viral oncolysis: increased immunogenicity of host cell antigen associated with influenza virus.病毒溶瘤作用：与流感病毒相关的宿主细胞抗原免疫原性增强。
J Exp Med. 1967 Jul 1;126(1):93-108. doi: 10.1084/jem.126.1.93.
本文引用的文献
1
NEWCASTLE DISEASE VIRUS AS AN ANTINEOPLASTIC AGENT.新城疫病毒作为一种抗肿瘤药物。
Cancer. 1965 Jul;18:863-8. doi: 10.1002/1097-0142(196507)18:7<863::aid-cncr2820180714>3.0.co;2-v.
Zotero 插件